A Virtual Reality Immune Dysregulation’s Support of Malignant Pathophysiology: Focus on Solid Tumorigenesis and Associated Therapeutic Targets

View Activity

FACULTY

Adil Daud, MD
HS Clinical Professor
Department of Medicine, Hematology/Oncology
USCF Director, Melanoma Clinical Research
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

PROGRAM OVERVIEW

This case-based online activity will cover the treatment and management of patients with cancer who are treated with or are eligible for treatment with immunotherapy.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professional involved in the management of patients with cancer who are treated with or are eligible for treatment with immunotherapy.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Describe the complex interactions between cancer cells, the tumor microenvironment, and the immune system and the mechanism of action of immune checkpoints inhibitors
  • Critically evaluate clinical data for checkpoint inhibition, with a focus on melanoma, non-small cell lung cancer, and head and neck squamous cell cancer
  • Recognize and manage immune-related adverse events (irAEs) associated with novel cancer immunotherapies

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity is planned and produced in accordance with ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with cancer. CNE Credits: 1.0 ANCC Contact Hour(s)

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Adil Daud, MD, is a consultant for Merck & Co., BMS, Genentech, Pfizer, and OncoSec. Dr. Daud also receives research grants from Merck & Co., Pfizer, OncoSec, Novartis, BMS, Incyte, and Exelixis. Dr. Daud has stocks with OncoSec and receives salary/personal fees from Incyte and Novartis.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
David Chatman, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at: www.medlearninggroup.com/privacy-policy/

RELEASE DATE: November 28, 2018

EXPIRATION DATE: November 28, 2019

View Activity

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.